Your browser doesn't support javascript.
loading
1Alpha,25-dihydroxyvitamin D3 decreases DNA binding of nuclear factor-kappaB in human fibroblasts.
Harant, H; Wolff, B; Lindley, I J.
Afiliación
  • Harant H; Department of Cellular and Molecular Biology, Novartis Research Institute, Vienna, Austria. Hanna.Harant@pharma.novartis.com
FEBS Lett ; 436(3): 329-34, 1998 Oct 09.
Article en En | MEDLINE | ID: mdl-9801142
ABSTRACT
1Alpha,25-dihydroxyvitamin D3 (1,25-(OH)2-D3), the active metabolite of vitamin D, can inhibit NF-kappaB activity in human MRC-5 fibroblasts, targeting DNA binding of NF-kappaB but not translocation of its subunits p50 and p65. The partial inhibition of NF-kappaB DNA binding by 1,25-(OH)2-D3 is dependent on de novo protein synthesis, suggesting that 1,25-(OH)2-D3 may regulate expression of cellular factors which contribute to reduced DNA binding of NF-kappaB. Although NF-kappaB binding is decreased by 1,25-(OH)2-D3 in MRC-5 cells, IL-8 and IL-6 mRNA levels are only moderately downregulated, demonstrating that inhibition of NF-kappaB DNA binding alone is not sufficient for optimal downregulation of these genes.
Asunto(s)
Buscar en Google
Bases de datos: MEDLINE Asunto principal: Calcitriol / ADN / FN-kappa B Límite: Humans Idioma: En Revista: FEBS Lett Año: 1998 Tipo del documento: Article País de afiliación: Austria
Buscar en Google
Bases de datos: MEDLINE Asunto principal: Calcitriol / ADN / FN-kappa B Límite: Humans Idioma: En Revista: FEBS Lett Año: 1998 Tipo del documento: Article País de afiliación: Austria